Autoimmune Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The autoimmune treatment market is segmented by Indication (Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Other Indications) By Drug Class, by Sales channel and Geography.

Market Snapshot

Autoimmune treatment market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.2 %
Autoimmune treatment market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The autoimmune treatment market is expected to grow with a CAGR of 4.2%, over the forecast period. The major factor attributing to the growth of the autoimmune treatment market is surge in prevalence of autoimmune diseases. According to NIH (National Institutes of Health) up to 23.5 million Americans have an autoimmune disease and the prevalance is increasing. Scientists have identified 80-100 various autoimmune diseases and assume at least 40 other diseases of having an autoimmune basis. The other factors that play a major role in taking the autoimmune treatment market to the next level are increasing investments in research and development of drugs for autoimmune diseases, technological advancements in diagnosis and awareness of the therapy. Rising government initiatives for regulating these diseases is also helping the growth of the market. However, higher costs of the therapeutics and low medical insurance coverage are constraining the market growth.

Scope of the Report

As per the scope of the report, in case of autoimmune diseases the body's immune system attacks healthy cells. The autoimmune diseases cannot be cured but they can control the intense immune response and bring down inflammation or at least reduce pain and inflammation. The market is segmented by Indication, Drug class, Sales channel and Geography.

By Indication
Rheumatic Disease
Multiple Sclerosis
Inflammatory Bowel Disease
Other Indications
By Drug Class
Other Drugs
By Sales Channel
Hospital Pharmacy
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Rheumatic Disease segment is Expected to Hold Large Market Share

  • The rheumatic disease segment is expected to dominate the market owing to the rising cases of diseases. Rheumatic diseases are described by swelling that affects the connecting structures of the body, mostly the joints, sometimes the tendons, ligaments, bones, and muscles.
  • The therapeutics for rheumatoid disease holds the significant share and expected to remain assertive during the forecast period, due to the rising geriatric population, increasing number of pipeline drugs and the increasing cases of arthritis, fibromyalgia, systemic lupus erythematosus, gout and others, and varied range and availability of progressive therapeutics for the treatment of these diseases.
  • In 2018, according to, around 1.3 million Americans were affected by Rheumatoid arthritis, and the number is increasing every year, which is a driving factor for the autoimmune treatment market.
Autoimmune treatment market Key Trends

North America Dominates the Market and Expected to do same in the Forecast Period

North America is expected to dominate the overall autoimmune treatment market, throughout the forecast period. This is due to factors such as the rising incidence and prevalence of autoimmune diseases like arthritis, lupus, multiple sclerosis, in the country. In the North America region, the United States holds the largest market share due to growing personal expenditure on healthcare. The healthcare commerce in the province is developing at a quick stride, resulting in the progress of the North America Autoimmune treatment market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Autoimmune treatment market Growth by Region

Competitive Landscape

The autoimmune treatment market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AbbVie, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, F. Hoffmann-La Roche AG, Astrazeneca Plc and Bristol-Myers Squibb Co.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in the Prevalence of Autoimmune Diseases

      2. 4.2.2 Increasing Investments in Research and development

      3. 4.2.3 Advancements in Diagnostic Methods

    3. 4.3 Market Restraints

      1. 4.3.1 Higher Cost of Therapeutics

      2. 4.3.2 Low Medical Insurance Coverage for Autoimmune Diseases

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Indication

      1. 5.1.1 Rheumatic Disease

      2. 5.1.2 Diabetes

      3. 5.1.3 Multiple Sclerosis

      4. 5.1.4 Inflammatory Bowel Disease

      5. 5.1.5 Other Indications

    2. 5.2 By Drug Class

      1. 5.2.1 Anti-Inflammatory

      2. 5.2.2 Anti-Hyperglycemics

      3. 5.2.3 NSAIDs

      4. 5.2.4 Interferons

      5. 5.2.5 Other Drugs

    3. 5.3 By Sales Channel

      1. 5.3.1 Hospital Pharmacy

      2. 5.3.2 Online

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abbvie

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 Johnson & Johnson

      4. 6.1.4 Eli Lilly and Company

      5. 6.1.5 Pfizer Inc.

      6. 6.1.6 F. Hoffmann-La Roche AG

      7. 6.1.7 Astrazeneca Plc

      8. 6.1.8 Bristol-Myers Squibb Co.

      9. 6.1.9 Lupin Limited

      10. 6.1.10 GlaxoSmithKline Plc

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Autoimmune Treatment Market market is studied from 2018 - 2026.

The Autoimmune Treatment Market is growing at a CAGR of 4.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

AbbVie, Amgen, Johnson and Johnson, Eli Lilly and Company, Pfizer Inc. are the major companies operating in Autoimmune Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!